engleski

Immunoglobulin G N-glycan analysis in asymptomatic and mild COVID 19

The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) occurred in 2019, and since then represents one of the major health problems around the world. SARS-CoV-2 causes a respiratory illness named coronavirus disease 2019 (COVID-19) with various clinical manifestations. Despite the increased knowledge about the SARS-CoV-2 virus, it still constitutes a significant threat to global health. Glycosylation mediates a wide variety of cellular functions and glycans represent one of the main defenses against pathogens. Glycosylation changes can modulate inflammatory responses and allow the virus to escape the immune system. As such, glycans have emerged as new biomarker candidates for COVID-19. Glycosylation of immunoglobulin G (IgG), the most abundant antibody in human serum, has been shown to differ between mild and severe COVID-19 cases, and in severe COVID-19 cases compared to healthy controls. However, mild and asymptomatic COVID-19 cases, as well as longitudinal changes during COVID-19 are still underexplored. In this study, we analyzed total serum IgG glycosylation from healthcare workers with COVID-19 from a hospital in Nottingham, UK. The samples were collected in multiple time points (before and after, or after tested seropositive for COVID-19), and symptoms ranged from asymptomatic to mild. IgG N-glycans were analyzed using ultra-high-performance liquid chromatography (UHPLC) after a rapid high-throughput in-solution deglycosylation and labeling of released N-glycans with InstantPC dye. IgG N-glycome does not change dramatically during the course of asymptomatic and mild COVID-19.

COVID-19 ; glycosylation ; IgG ; SARS-CoV-2

nije evidentirano